Summary of the payer’s published policy. Not a coverage determination — confirm with the payer before submitting.
Recorded changes
83,427 on record
Recorded policy changes, newest first| Recorded | Payer | Policy | Change |
|---|
| Aug 2, 2026 | Independence Blue Cross | LabiaplastyPayerPolicy · IBX-COMMERCIAL-11-06-09 | New policy |
|---|
| Aug 2, 2026 | Independence Blue Cross | Knee OrthosesPayerPolicy · IBX-COMMERCIAL-05-00-47 | New policy |
|---|
| Aug 2, 2026 | Independence Blue Cross | Islet Cell Transplantation, including use of Donislecel-jujn (Lantidra)PayerPolicy · IBX-COMMERCIAL-11-04-01 | New policy |
|---|
| Aug 2, 2026 | Independence Blue Cross | Isatuximab-irfc (Sarclisa)PayerPolicy · IBX-COMMERCIAL-08-00-46 | New policy |
|---|
| Aug 2, 2026 | Independence Blue Cross | Ipilimumab (Yervoy)PayerPolicy · IBX-COMMERCIAL-08-01-01 | New policy |
|---|
| Aug 2, 2026 | Independence Blue Cross | In Vivo Allergy Sensitivity TestingPayerPolicy · IBX-COMMERCIAL-07-00-05 | New policy |
|---|
| Aug 2, 2026 | Independence Blue Cross | In Vitro Chemosensitivity and Chemoresistance AssaysPayerPolicy · IBX-COMMERCIAL-06-02-14 | New policy |
|---|
| Aug 2, 2026 | Independence Blue Cross | In Vitro Allergy TestingPayerPolicy · IBX-COMMERCIAL-06-02-26 | New policy |
|---|
| Aug 2, 2026 | Independence Blue Cross | Intravitreal Injection of Vascular Endothelial Growth Factor (VEGF) Antagonists, VEGF Biosimilars, and Combination VEGF/Angiopoietin-2 (Ang-2) InhibitorsPayerPolicy · IBX-COMMERCIAL-08-00-74AC-04AF371E67 | New policy |
|---|
| Aug 2, 2026 | Independence Blue Cross | Intravenous Ketamine (Ketalar) and Intranasal Esketamine (Spravato)PayerPolicy · IBX-COMMERCIAL-08-01-80 | New policy |
|---|
| Aug 2, 2026 | Independence Blue Cross | Intravenous Infliximab and Related BiosimilarsPayerPolicy · IBX-COMMERCIAL-08-00-34 | New policy |
|---|
| Aug 2, 2026 | Independence Blue Cross | Intravenous Chelation TherapyPayerPolicy · IBX-COMMERCIAL-07-00-02 | New policy |
|---|
| Aug 2, 2026 | Independence Blue Cross | Intravenous (IV) Iron PreparationsPayerPolicy · IBX-COMMERCIAL-08-02-29 | New policy |
|---|
| Aug 2, 2026 | Independence Blue Cross | Intravenous (IV) Administration of Fluids as a Treatment of a Medical Condition or for the Preparation of Pharmaceuticals, Biologics, and other SubstancesPayerPolicy · IBX-COMMERCIAL-00-01-45 | New policy |
|---|
| Aug 2, 2026 | Independence Blue Cross | Intraoperative Neurophysiological Monitoring (INM)PayerPolicy · IBX-COMMERCIAL-07-03-14 | New policy |
|---|
| Aug 2, 2026 | Independence Blue Cross | Intra-Articular Injection of Hyaluronan for the Treatment of OsteoarthritisPayerPolicy · IBX-COMMERCIAL-11-14-07 | New policy |
|---|
| Aug 2, 2026 | Independence Blue Cross | Interleukin-5 (IL-5) Antagonist (e.g., Cinqair, Exdensur)PayerPolicy · IBX-COMMERCIAL-08-01-23 | New policy |
|---|
| Aug 2, 2026 | Independence Blue Cross | Intensity-Modulated Radiation Therapy (IMRT) (Independence Administrators)PayerPolicy · IBX-COMMERCIAL-09-00-17 | New policy |
|---|
| Aug 2, 2026 | Independence Blue Cross | Insulin Pumps and Long-Term Interstitial Continuous Glucose Monitoring Systems (IBC)PayerPolicy · IBX-COMMERCIAL-05-00-79 | New policy |
|---|
| Aug 2, 2026 | Independence Blue Cross | Instrument-Based Vision ScreeningPayerPolicy · IBX-COMMERCIAL-07-13-12 | New policy |
|---|
| Aug 2, 2026 | Independence Blue Cross | Insertion of Implantable Infusion PumpsPayerPolicy · IBX-COMMERCIAL-11-15-03 | New policy |
|---|
| Aug 2, 2026 | Independence Blue Cross | Injectable Dermal Fillers for Cosmetic ProceduresPayerPolicy · IBX-COMMERCIAL-05-00-62 | New policy |
|---|
| Aug 2, 2026 | Independence Blue Cross | Inebilizumab-cdon (Uplizna)PayerPolicy · IBX-COMMERCIAL-08-01-68 | New policy |
|---|
| Aug 2, 2026 | Independence Blue Cross | Inclisiran (Leqvio)PayerPolicy · IBX-COMMERCIAL-08-01-91 | New policy |
|---|
| Aug 2, 2026 | Independence Blue Cross | Implantable Cardioverter DefibrillatorsPayerPolicy · IBX-COMMERCIAL-05-00-77 | New policy |
|---|
| Aug 2, 2026 | Independence Blue Cross | Immune Globulin Intravenous (IVIG), Subcutaneous (SCIG)PayerPolicy · IBX-COMMERCIAL-08-00-13AO-68CBFF4879 | New policy |
|---|
| Aug 2, 2026 | Independence Blue Cross | Immune Cell Function AssayPayerPolicy · IBX-COMMERCIAL-06-02-37 | New policy |
|---|
| Aug 2, 2026 | Independence Blue Cross | Imetelstat (Rytelo)PayerPolicy · IBX-COMMERCIAL-08-02-30 | New policy |
|---|
| Aug 2, 2026 | Independence Blue Cross | Hyperthermic Intraperitoneal Chemotherapy for Select Intra-abdominal and Pelvic MalignanciesPayerPolicy · IBX-COMMERCIAL-11-00-13 | New policy |
|---|
| Aug 2, 2026 | Independence Blue Cross | Human Immunodeficiency Virus (HIV) Genotyping and Phenotyping (Independence Administrators)PayerPolicy · IBX-COMMERCIAL-06-02-09 | New policy |
|---|
| Aug 2, 2026 | Independence Blue Cross | Hospital ReadmissionsPayerPolicy · IBX-COMMERCIAL-00-01-47 | New policy |
|---|
| Aug 2, 2026 | Independence Blue Cross | Hospital Beds and AccessoriesPayerPolicy · IBX-COMMERCIAL-05-00-56 | New policy |
|---|
| Aug 2, 2026 | Independence Blue Cross | Hospice CarePayerPolicy · IBX-COMMERCIAL-02-02-01 | New policy |
|---|
| Aug 2, 2026 | Independence Blue Cross | Home-Use Light Box for the Treatment of Seasonal Affective Disorder (SAD)PayerPolicy · IBX-COMMERCIAL-05-00-69 | New policy |
|---|
| Aug 2, 2026 | Independence Blue Cross | Home Prothrombin Time MonitoringPayerPolicy · IBX-COMMERCIAL-05-00-26 | New policy |
|---|
| Aug 2, 2026 | Independence Blue Cross | Home Oxygen TherapyPayerPolicy · IBX-COMMERCIAL-05-00-58 | New policy |
|---|
| Aug 2, 2026 | Independence Blue Cross | Home Health Care ServicesPayerPolicy · IBX-COMMERCIAL-02-01-01 | New policy |
|---|
| Aug 2, 2026 | Independence Blue Cross | Home-Based Sleep StudiesPayerPolicy · IBX-COMMERCIAL-07-03-01 | New policy |
|---|
| Aug 2, 2026 | Independence Blue Cross | High-Technology Radiology ServicesPayerPolicy · IBX-COMMERCIAL-09-00-46AW-F6DFDAAA7C | New policy |
|---|
| Aug 2, 2026 | Independence Blue Cross | High Osmolar Contrast AgentsPayerPolicy · IBX-COMMERCIAL-09-00-13 | New policy |
|---|
| Aug 2, 2026 | Independence Blue Cross | High-Frequency Chest Wall Oscillation DevicesPayerPolicy · IBX-COMMERCIAL-05-00-14 | New policy |
|---|
| Aug 2, 2026 | Independence Blue Cross | Hematopoietic Stem Cell TransplantationPayerPolicy · IBX-COMMERCIAL-11-07-01AC-3F45305192 | New policy |
|---|
| Aug 2, 2026 | Independence Blue Cross | Hair Transplants and Cranial Prostheses (Wigs)PayerPolicy · IBX-COMMERCIAL-11-08-01 | New policy |
|---|
| Aug 2, 2026 | Independence Blue Cross | Guselkumab (Tremfya) Injection for Intravenous UsePayerPolicy · IBX-COMMERCIAL-08-02-33 | New policy |
|---|
| Aug 2, 2026 | Independence Blue Cross | Guidelines for Home Care Visits Following Inpatient Maternity StayPayerPolicy · IBX-COMMERCIAL-00-05-01 | New policy |
|---|
| Aug 2, 2026 | Independence Blue Cross | Ground Ambulance Services (Emergency and Nonemergency) (Independence)PayerPolicy · IBX-COMMERCIAL-12-04-02 | New policy |
|---|
| Aug 2, 2026 | Independence Blue Cross | Golimumab (Simponi Aria) Intravenous (IV) InjectionPayerPolicy · IBX-COMMERCIAL-08-01-15 | New policy |
|---|
| Aug 2, 2026 | Independence Blue Cross | Glofitamab-gxbm (Columvi)PayerPolicy · IBX-COMMERCIAL-08-02-07 | New policy |
|---|
| Aug 2, 2026 | Independence Blue Cross | Givosiran (Givlaari) and Panhematin (Hemin)PayerPolicy · IBX-COMMERCIAL-08-00-21 | New policy |
|---|
| Aug 2, 2026 | Independence Blue Cross | Genetic Testing for Inherited Susceptibility to Colon Cancer and Microsatellite Instability Testing (Familial Adenomatous Polyposis and Lynch Syndrome) (Independence Administrators)PayerPolicy · IBX-COMMERCIAL-06-02-10 | New policy |
|---|